Ira Pastan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6808644/publications.pdf

Version: 2024-02-01

405	28,439	5126 86	8627 151
papers	citations	h-index	g-index

406	406	406	17887
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER. Annual Review of Pharmacology and Toxicology, 1999, 39, 361-398.	4.2	1,940
2	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3360-3365.	3.3	758
3	Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. New England Journal of Medicine, 2001, 345, 241-247.	13.9	509
4	Immunotoxin therapy of cancer. Nature Reviews Cancer, 2006, 6, 559-565.	12.8	475
5	Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell, 1987, 48, 129-136.	13.5	460
6	Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell and Molecular Genetics, 1985, 11, 117-126.	0.7	446
7	A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature, 1989, 339, 394-397.	13.7	435
8	Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies. Journal of Clinical Oncology, 2000, 18, 1622-1636.	0.8	416
9	Mesothelin. Clinical Cancer Research, 2004, 10, 3937-3942.	3.2	394
10	Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers. Clinical Cancer Research, 2007, 13, 5144-5149.	3.2	351
11	Immunotoxin Treatment of Cancer*. Annual Review of Medicine, 2007, 58, 221-237.	5.0	340
12	Recombinant Toxins as Novel Therapeutic Agents. Annual Review of Biochemistry, 1992, 61, 331-354.	5.0	328
13	Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Molecular Cancer, 2006, 5, 50.	7.9	325
14	Recombinant toxins for cancer treatment. Science, 1991, 254, 1173-1177.	6.0	298
15	Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. Nature, 1984, 309, 806-810.	13.7	294
16	Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 2012, 30, 1822-1828.	0.8	287
17	Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature, 1988, 335, 369-372.	13.7	266
18	Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies. Journal of Clinical Oncology, 2005, 23, 6719-6729.	0.8	262

#	Article	IF	Citations
19	Detection and Quantitation of Serum Mesothelin, a Tumor Marker for Patients with Mesothelioma and Ovarian Cancer. Clinical Cancer Research, 2006, 12, 447-453.	3.2	256
20	Amines inhibit the clustering of Î±2-macroglobulin and EGF on the fibroblast cell surface. Nature, 1979, 277, 661-663.	13.7	250
21	Human P-Glycoprotein Exhibits Reduced Affinity for Substrates during a Catalytic Transition State. Biochemistry, 1998, 37, 5010-5019.	1.2	245
22	Lac DNA, RNA Polymerase and Cyclic AMP Receptor Protein, Cyclic AMP, Lac Repressor and Inducer are the Essential Elements for Controlled Lac Transcription. Nature: New Biology, 1971, 231, 139-142.	4.5	244
23	Mesothelin Immunotherapy for Cancer: Ready for Prime Time?. Journal of Clinical Oncology, 2016, 34, 4171-4179.	0.8	244
24	Improving antibody affinity by mimicking somatic hypermutation in vitro. Nature Biotechnology, 1999, 17, 568-572.	9.4	238
25	Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. International Journal of Cancer, 1992, 50, 373-381.	2.3	227
26	Genetic Engineering of Glomerular Sclerosis in the MouseviaControl of Onset and Severity of Podocyte-Specific Injury. Journal of the American Society of Nephrology: JASN, 2005, 16, 1013-1023.	3.0	225
27	Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Journal of Neuro-Oncology, 2003, 65, 27-35.	1.4	222
28	ATPâ€binding properties of P glycoprotein from multidrugâ€resistant KB cells. FASEB Journal, 1987, 1, 51-54.	0.2	209
29	Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P. Clinical Cancer Research, 2009, 15, 5274-5279.	3.2	209
30	A guide to taming a toxinâ€ƒâ€“â€ƒrecombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS Journal, 2011, 278, 4683-4700.	2.2	209
31	Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology, 2009, 27, 2983-2990.	0.8	208
32	Treatment of advanced solid tumors with immunotoxin LMBâ€“1: An antibody linked to Pseudomonas exotoxin. Nature Medicine, 1996, 2, 350-353.	15.2	206
33	Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy. Cancer Research, 2014, 74, 2907-2912.	0.4	204
34	Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. Clinical Cancer Research, 2011, 17, 6398-6405.	3.2	201
35	Mesothelin Is Not Required for Normal Mouse Development or Reproduction. Molecular and Cellular Biology, 2000, 20, 2902-2906.	1.1	198
36	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression. Science Translational Medicine, 2013, 5, 208ra147.	5.8	198

#	Article	IF	Citations
37	Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers. Clinical Cancer Research, 2010, 16, 6132-6138.	3.2	190
38	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia, 2018, 32, 1768-1777.	3.3	184
39	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology, 2008, 10, 320-329.	0.6	179
40	A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood, 2009, 113, 3792-3800.	0.6	174
41	Regulation of Cell Motility by Cyclic AMP. Nature, 1972, 235, 54-56.	13.7	170
42	The visualization of fluorescent proteins in living cells by video intensification microscopy (VIM). Cell, 1978, 13, 501-507.	13.5	168
43	Effects of Calcium on ACTH Stimulation of the Adrenal: Separation of Hormone Binding from Adenyl Cyclase Activation. Nature, 1970, 228, 864-866.	13.7	166
44	Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo. Journal of Immunology, 2007, 179, 4919-4928.	0.4	162
45	Responses in Refractory Hairy Cell Leukemia to a Recombinant Immunotoxin. Blood, 1999, 94, 3340-3348.	0.6	161
46	Advances in Anticancer Immunotoxin Therapy. Oncologist, 2015, 20, 176-185.	1.9	161
47	Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma. Clinical Cancer Research, 2014, 20, 5927-5936.	3.2	158
48	An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11311-11316.	3.3	157
49	3D Culture Supports Long-Term Expansion of Mouse and Human Nephrogenic Progenitors. Cell Stem Cell, 2016, 19, 516-529.	5.2	153
50	Localization of Mesothelin in Epithelial Ovarian Cancer. Applied Immunohistochemistry and Molecular Morphology, 2005, 13, 243-247.	0.6	152
51	Effect of Rho on Transcription of Bacterial Operons. Nature: New Biology, 1973, 241, 260-264.	4.5	150
52	Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11782-11787.	3.3	145
53	Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma. American Journal of Surgical Pathology, 1992, 16, 259-268.	2.1	144
54	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for frontâ€line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer, 2014, 120, 3311-3319.	2.0	144

#	Article	IF	Citations
55	Engineering antibody Fv fragments for cancer detection and therapy: Bisulfide-stabilized Fv fragments. Nature Biotechnology, 1996, 14, 1239-1245.	9.4	143
56	Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients. Clinical Cancer Research, 2005, 11, 3814-3820.	3.2	140
57	Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial. Clinical Cancer Research, 2010, 16, 1894-1903.	3.2	139
58	Both ATP Sites of Human P-Glycoprotein Are Essential but Not Symmetric. Biochemistry, 1999, 38, 13887-13899.	1.2	137
59	Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clinical Cancer Research, 2002, 8, 995-1002.	3.2	135
60	Designed heterodimerizing leucine zippers with a ranger of pIs and stabilities up to 10-15 M. Protein Science, 2001, 10, 649-655.	3.1	130
61	Genetic basis of multidrug resistance of tumor cells. Journal of Bioenergetics and Biomembranes, 1990, 22, 593-618.	1.0	129
62	Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2015, 62, 964-969.	0.8	129
63	Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.. Journal of Clinical Oncology, 1991, 9, 2095-2103.	0.8	128
64	Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates. Cancer Research, 2011, 71, 6300-6309.	0.4	119
65	Mesothelin Expression in Human Lung Cancer. Clinical Cancer Research, 2007, 13, 1571-1575.	3.2	118
66	Removing T-cell epitopes with computational protein design. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8577-8582.	3.3	115
67	Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-pseudomonas exotoxin chimeric protein. International Journal of Cancer, 1994, 58, 574-581.	2.3	112
68	Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors. Blood, 1997, 90, 2020-2026.	0.6	112
69	Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro-Oncology, 2007, 9, 343-353.	0.6	112
70	Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity. Cancer Research, 2008, 68, 6300-6305.	0.4	111
71	N6,O2â€²-Dibutyryl Adenosine 3â€²,5â€²-Monophosphate induces Pigment Production in Melanoma Cells. Nature: New Biology, 1972, 237, 267-268.	4.5	109
72	CAT-8015: A Second-GenerationPseudomonasExotoxin Aâ€“Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies. Clinical Cancer Research, 2009, 15, 832-839.	3.2	107

#	Article	IF	Citations
73	Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients. Journal of Immunology, 2006, 177, 8822-8834.	0.4	104
74	Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8571-8576.	3.3	104
75	New Immunotoxins Targeting CD123, a Stem Cell Antigen on Acute Myeloid Leukemia Cells. Journal of Immunotherapy, 2007, 30, 607-613.	1.2	102
76	Immunotoxins for leukemia. Blood, 2014, 123, 2470-2477.	0.6	102
77	Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma. Clinical Cancer Research, 2006, 12, 4225-4231.	3.2	101
78	Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART. PLoS Pathogens, 2014, 10, e1003872.	2.1	101
79	Structural Flexibility of the Linker Region of Human P-Glycoprotein Permits ATP Hydrolysis and Drug Transport. Biochemistry, 1998, 37, 13660-13673.	1.2	99
80	Podocyte Injury Damages Other Podocytes. Journal of the American Society of Nephrology: JASN, 2011, 22, 1275-1285.	3.0	98
81	Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5742-5747.	3.3	97
82	In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin. Journal of Biological Chemistry, 2005, 280, 607-617.	1.6	96
83	Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development. Molecular Cancer Therapeutics, 2012, 11, 517-525.	1.9	96
84	Intracerebral Infusate Distribution by Convection-enhanced Delivery in Humans with Malignant Gliomas: Descriptive Effects of Target Anatomy and Catheter Positioning. Operative Neurosurgery, 2007, 60, ONS-89-ONS-99.	0.4	95
85	Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Engineering, Design and Selection, 1994, 7, 697-704.	1.0	94
86	Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. Journal of Cellular Physiology, 2000, 183, 108-116.	2.0	91
87	Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based onPseudomonasexotoxin A. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3597-603.	3.3	89
88	In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer. Molecular Cancer Therapeutics, 2014, 13, 2040-2049.	1.9	89
89	Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunology, Immunotherapy, 2003, 52, 338-341.	2.0	88
90	A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity. Molecular Cancer Therapeutics, 2013, 12, 48-57.	1.9	87

#	Article	IF	Citations
91	Immunogenicity of therapeutic recombinant immunotoxins. Immunological Reviews, 2016, 270, 152-164.	2.8	85
92	Role ofCAS, a Human Homologue to the Yeast Chromosome Segregation GeneCSE1, in Toxin and Tumor Necrosis Factor Mediated Apoptosis. Biochemistry, 1996, 35, 6891-6899.	1.2	83
93	Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. , 1999, 81, 148-155.		81
94	Recombinant immunotoxins for treating cancer. International Journal of Medical Microbiology, 2004, 293, 577-582.	1.5	81
95	Interleukin 6 Receptor mRNA in Prostate Carcinomas and Benign Prostate Hyperplasia. Journal of Urology, 1994, 151, 1396-1399.	0.2	80
96	Contribution to Substrate Specificity and Transport of Nonconserved Residues in Transmembrane Domain 12 of Human P-Glycoproteinâ€. Biochemistry, 1998, 37, 16400-16409.	1.2	80
97	A model for obesity and gigantism due to disruption of the Ankrd26 gene. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 270-275.	3.3	79
98	Cytotoxic activities of a fusion protein comprised of TGFÎ± and Pseudomonas exotoxin. FASEB Journal, 1989, 3, 2647-2652.	0.2	78
99	HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity. Clinical Cancer Research, 2005, 11, 1545-1550.	3.2	78
100	Decreased binding of epidermal growth factor to BALB/c 3T3 mutant cells defective in glycoprotein synthesis. Nature, 1978, 272, 68-70.	13.7	75
101	Reversal of Drug Resistance in a Human Colon Cancer Xenograft Expressing MDR1 Complementary DNA by In Vivo Administration of MRK-16 Monoclonal Antibody. Journal of the National Cancer Institute, 1991, 83, 1386-1391.	3.0	75
102	POTE, a highly homologous gene family located on numerous chromosomes and expressed in prostate, ovary, testis, placenta, and prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16975-16980.	3.3	75
103	Immunotoxins in the Treatment of Hematologic Malignancies. Current Drug Targets, 2006, 7, 1301-1311.	1.0	75
104	Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17099-17104.	3.3	75
105	Cyclic AMP increases the Adhesion of Fibroblasts to Substratum. Nature: New Biology, 1972, 236, 247-249.	4.5	74
106	Synergistic Antitumor Activity of Taxol and Immunotoxin SS1P in Tumor-Bearing Mice. Clinical Cancer Research, 2006, 12, 4695-4701.	3.2	73
107	Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeuticsâ˜†. Advanced Drug Delivery Reviews, 2009, 61, 977-985.	6.6	73
108	Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. International Journal of Cancer, 2000, 87, 86-94.	2.3	70

#	Article	IF	Citations
109	Recombinant Immunotoxins in the Treatment of Cancer. , 2004, 248, 503-518.		70
110	Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4575-4582.	3.3	70
111	Single-chain immunotoxin fusions between anti-tac and Pseudomonas exotoxin: Relative importance of the two toxin disulfide bonds. Bioconjugate Chemistry, 1993, 4, 112-120.	1.8	69
112	Cytotoxicity of the antiâ€CD22 immunotoxin HA22 (CATâ€8015) against paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 2010, 150, 352-358.	1.2	69
113	Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. International Journal of Cancer, 2000, 88, 962-969.	2.3	68
114	Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers. Molecular Cancer Therapeutics, 2014, 13, 2653-2661.	1.9	68
115	Induction of Hyperintense Signal on T2-Weighted MR Images Correlates with Infusion Distribution from Intracerebral Convection-Enhanced Delivery of a Tumor-Targeted Cytotoxin. American Journal of Roentgenology, 2007, 188, 703-709.	1.0	67
116	Selective Elimination of Human Regulatory T Lymphocytes In Vitro With the Recombinant Immunotoxin LMB-2. Journal of Immunotherapy, 2006, 29, 208-214.	1.2	66
117	High mesothelin expression in advanced lung adenocarcinoma is associated withKRASmutations and a poor prognosis. Oncotarget, 2015, 6, 11694-11703.	0.8	66
118	Renaturation of a Singleâ€“Chain Immunotoxin Facilitated by Chaperones and Protein Disulfide Isomerase. Nature Biotechnology, 1992, 10, 682-685.	9.4	65
119	New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-Activated Cell Sorting, Western Blotting, and ELISA. Clinical Cancer Research, 2005, 11, 5840-5846.	3.2	65
120	Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood, 2004, 103, 2718-2726.	0.6	64
121	Topology of NGEP, a Prostate-Specific Cell:Cell Junction Protein Widely Expressed in Many Cancers of Different Grade Level. Cancer Research, 2008, 68, 6306-6312.	0.4	64
122	Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors. Journal of Controlled Release, 2012, 162, 218-224.	4.8	64
123	Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood, 2018, 131, 2331-2334.	0.6	64
124	Pseudomonas Exotoxin A-Mediated Apoptosis Is Bak Dependent and Preceded by the Degradation of Mcl-1. Molecular and Cellular Biology, 2010, 30, 3444-3452.	1.1	63
125	Retroviruses expressing different levels of the normal epidermal growth factor receptor: Biological properties and new bioassay. Journal of Cellular Biochemistry, 1989, 39, 153-166.	1.2	60
126	A Single Amino Acid Residue Contributes to Distinct Mechanisms of Inhibition of the Human Multidrug Transporter by Stereoisomers of the Dopamine Receptor Antagonist Flupentixol. Biochemistry, 1999, 38, 6630-6639.	1.2	60

#	Article	IF	Citations
127	Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma. Journal of Immunotherapy, 2000, 23, 473-479.	1.2	60
128	Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clinical Cancer Research, 2002, 8, 3520-6.	3.2	60
129	Inhibition of TNF-Î± Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2. Journal of Immunology, 2000, 165, 7150-7156.	0.4	59
130	POTE Paralogs Are Induced and Differentially Expressed in Many Cancers. Cancer Research, 2006, 66, 52-56.	0.4	59
131	High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy. Clinical Cancer Research, 2008, 14, 7981-7986.	3.2	59
132	Targeting malignant B cells with an immunotoxin against ROR1. MAbs, 2012, 4, 349-361.	2.6	59
133	Efficient Expression of Drug-selectable Genes in Retroviral Vectors Under Control of an Internal Ribosome Entry Site. Nature Biotechnology, 1994, 12, 694-698.	9.4	58
134	Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation. Kidney International, 2014, 85, 1068-1077.	2.6	58
135	Ankrd26 Gene Disruption Enhances Adipogenesis of Mouse Embryonic Fibroblasts*. Journal of Biological Chemistry, 2011, 286, 27761-27768.	1.6	57
136	Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. Kidney International, 2013, 83, 1065-1075.	2.6	57
137	Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood, 2017, 130, 1620-1627.	0.6	57
138	Interleukin-13 Receptors on Human Prostate Carcinoma Cell Lines Represent a Novel Target for a Chimeric Protein Composed of IL-13 and a Mutated Form of Pseudomonas Exotoxin. Journal of Urology, 1997, 158, 948-953.	0.2	56
139	Frequent expression of the tumor antigen cak1 in squamous-cell carcinomas. International Journal of Cancer, 1992, 51, 548-554.	2.3	55
140	Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation. Frontiers in Immunology, 2020, 11, 1261.	2.2	55
141	Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. Proteins: Structure, Function and Bioinformatics, 1994, 19, 35-47.	1.5	54
142	Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study. Neuro-Oncology, 2005, 7, 90-96.	0.6	54
143	Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10666-10671.	3.3	54
144	Molecular manipulations of the multidrug transporter: a new role for transgenic mice ¹. FASEB Journal, 1991, 5, 2523-2528.	0.2	53

#	Article	IF	Citations
145	Verapamil enhances the toxicity of conjugates of epidermal growth factor withPseudomonas exotoxin and antitransferrin receptor withpseudomonas exotoxin. Journal of Cellular Physiology, 1984, 120, 271-279.	2.0	52
146	TargetingPseudomonasexotoxin to hematologic malignancies. Seminars in Cancer Biology, 1995, 6, 297-306.	4.3	52
147	A novel highâ€affinity human monoclonal antibody to mesothelin. International Journal of Cancer, 2011, 128, 2020-2030.	2.3	52
148	Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins. American Journal of Pathology, 2018, 188, 1736-1743.	1.9	52
149	Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. , 1997, 72, 512-517.		51
150	Pretreatment with Rituximab Does Not Inhibit the Human Immune Response against the Immunogenic Protein LMB-1. Clinical Cancer Research, 2004, 10, 16-18.	3.2	51
151	Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. Journal of Hematology and Oncology, 2021, 14, 35.	6.9	51
152	Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6898-6903.	3.3	49
153	Role of Cyclic Adenosine 3â€²,5â€²-Monophosphate and the Cyclic Adenosine 3â€²,5â€²-Monophosphate Receptor Protein in the Initiation of lac Transcription. Journal of Biological Chemistry, 1971, 246, 7343-7348.	1.6	49
154	Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. Clinical Cancer Research, 2016, 22, 310-318.	3.2	48
155	Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. Journal of Neuro-Oncology, 2010, 98, 1-7.	1.4	46
156	Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated Î²1-integrin endocytosis. American Journal of Physiology - Renal Physiology, 2015, 308, F614-F626.	1.3	45
157	Characterization of a reâ€engineered, mesothelinâ€targeted Pseudomonas exotoxin fusion protein for lung cancer therapy. Molecular Oncology, 2016, 10, 1317-1329.	2.1	45
158	Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E733-E742.	3.3	45
159	Sequence rearrangement and duplication of double stranded fibronectin cDNA probably occurring during cDNA synthesis by AMV reverse transcriptase and Escherichia coli DNA polymerase I. Nucleic Acids Research, 1980, 8, 3055-3064.	6.5	44
160	Molecular cloning and expression of a cDNA encoding a protein detected by the ki antibody from an ovarian carcinoma (OVCAR-3) cell line. International Journal of Cancer, 1994, 57, 90-97.	2.3	44
161	Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-TAC Fv fragment and truncatedpseudomonas exotoxin. International Journal of Cancer, 1994, 58, 142-149.	2.3	44
162	Expression Cloning of cDNAs That Render Cancer Cells Resistant to Pseudomonas and Diphtheria Toxin and Immunotoxins. Molecular Medicine, 1995, 1, 206-216.	1.9	44

#	Article	IF	Citations
163	Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nature Medicine, 1999, 5, 817-822.	15.2	44
164	Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts. Clinical Cancer Research, 2011, 17, 3697-3705.	3.2	44
165	Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3501-E3508.	3.3	44
166	Cyclic AMP and Growth of Fibroblasts: Effect of Environmental pH. Nature: New Biology, 1973, 242, 78-80.	4.5	43
167	DNA immunization followed by a single boost with cells: a protein-free immunization protocol for production of monoclonal antibodies against the native form of membrane proteins. Journal of Immunological Methods, 2003, 280, 59-72.	0.6	43
168	Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths. Gene, 2004, 337, 45-53.	1.0	43
169	Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs. PLoS Pathogens, 2010, 6, e1000803.	2.1	43
170	Evolution and expression of chimeric POTE-actin genes in the human genome. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17885-17890.	3.3	42
171	Engineered Antiâ€GPC3 Immunotoxin, HN3â€ABDâ€T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention. Hepatology, 2020, 71, 1696-1711.	3.6	42
172	New Potent Verapamil Derivatives that Reverse Multidrug Resistance in Human Renal Carcinoma Cells and in Transgenic Mice Expressing the Human MDR 1 Gene. Journal of Urology, 1991, 146, 447-453.	0.2	41
173	FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood, 2008, 111, 338-343.	0.6	41
174	Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity. Oncotarget, 2016, 7, 29916-29926.	0.8	41
175	Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA). European Journal of Nuclear Medicine and Molecular Imaging, 1994, 21, 640-646.	2.2	40
176	Antigen Shedding May Improve Efficiencies for Delivery of Antibody-Based Anticancer Agents in Solid Tumors. Cancer Research, 2012, 72, 3143-3152.	0.4	40
177	Retroviral transfer of a chimeric multidrug resistanceâ€adenosine deaminase gene. FASEB Journal, 1990, 4, 1501-1507.	0.2	39
178	Podocyte Injuryâ€“Driven Lipid Peroxidation Accelerates the Infiltration of Glomerular Foam Cells in Focal Segmental Glomerulosclerosis. American Journal of Pathology, 2015, 185, 2118-2131.	1.9	39
179	On the Mechanism of Action of lac Repressor. Nature: New Biology, 1971, 233, 67-70.	4.5	38
180	PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3058-3063.	3.3	38

#	Article	IF	Citations
181	A primate-specific POTE-actin fusion protein plays a role in apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 1237-1244.	2.2	38
182	A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake. Cancer Research, 2010, 70, 1082-1089.	0.4	38
183	New Life for Immunotoxin Cancer Therapy. Clinical Cancer Research, 2016, 22, 1055-1058.	3.2	38
184	Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy. Oncotarget, 2017, 8, 32450-32460.	0.8	38
185	Cancer vaccine strategies: translation from mice to human clinical trials. Cancer Immunology, Immunotherapy, 2018, 67, 1863-1869.	2.0	38
186	Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. Oncotarget, 2017, 8, 26744-26754.	0.8	38
187	Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging. Oncotarget, 2015, 6, 4496-4504.	0.8	38
188	Domain II of Pseudomonas Exotoxin A Arrests the Transfer of Translocating Nascent Chains into Mammalian Microsomes. Biochemistry, 1994, 33, 5894-5900.	1.2	37
189	New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma. Scientific Reports, 2015, 5, 9928.	1.6	37
190	Loss of diphthamide pre-activates NF-Î¹B and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10732-10737.	3.3	37
191	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. Cancer Immunology Research, 2017, 5, 685-694.	1.6	37
192	Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patientâ€™s Bedside to Evaluation in Preclinical Models. Toxins, 2019, 11, 20.	1.5	37
193	A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2011, 118, 248-248.	0.6	37
194	PRAC: A novel small nuclear protein that is specifically expressed in human prostate and colon. Prostate, 2001, 47, 125-131.	1.2	36
195	Tubulointerstitial fibrosis can sensitize the kidney to subsequent glomerular injury. Kidney International, 2017, 92, 1395-1403.	2.6	36
196	A bivalent disulfide-stabilized fv with improved antigen binding to erbb2. Journal of Molecular Biology, 1998, 281, 475-483.	2.0	35
197	A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice. Journal of Immunotherapy, 2010, 33, 297-304.	1.2	35
198	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research, 2020, 26, 828-836.	3.2	35

#	Article	IF	Citations
199	Regulation of intracellular calcium in chick embryo fibroblast: Calcium uptake by the microsomal fraction. Journal of Cellular Physiology, 1977, 91, 289-296.	2.0	34
200	Pseudomonas Exotoxin Conjugated to Monoclonal Antibody MRK16 Specifically Kills Multidrug Resistant Cells in Cultured Renal Carcinomas and In Mdr-Transgenic Mice. Journal of Urology, 1993, 149, 174-178.	0.2	34
201	Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. International Journal of Cancer, 1995, 62, 351-355.	2.3	34
202	An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies. Leukemia Research, 2014, 38, 1224-1229.	0.4	34
203	Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors. Molecular Cancer Therapeutics, 2015, 14, 2789-2796.	1.9	34
204	ATP and GTP as alternative energy sources for vinblastine transport by P-170 in KB-V1 plasma membrane vesicles. FEBS Letters, 1992, 304, 256-260.	1.3	33
205	111Indium-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. , 1999, 80, 559-563.		33
206	Recognition of Mesothelin by the Therapeutic Antibody MORAb-009. Journal of Biological Chemistry, 2012, 287, 33123-33131.	1.6	33
207	Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. Biomaterials, 2013, 34, 8718-8725.	5.7	33
208	Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo. Cellular and Molecular Immunology, 2017, 14, 432-442.	4.8	33
209	5â€™UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 18.	6.9	33
210	Cytotoxic activity of chimeric proteins composed of acidic fibroblast growth factor and Pseudomonas exotoxin on a variety of cell types. FASEB Journal, 1991, 5, 2843-2849.	0.2	32
211	Cse1l Is Essential for Early Embryonic Growth and Development. Molecular and Cellular Biology, 2001, 21, 7020-7024.	1.1	32
212	Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patientâ€“Derived Xenografts and Mesothelin as a Biomarker of Tumor Response. Clinical Cancer Research, 2017, 23, 1564-1574.	3.2	32
213	Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clinical Cancer Research, 2002, 8, 2345-55.	3.2	32
214	Identification of epitopes on a mutant form ofPseudomonas exotoxin using serum from humans treated withPseudomonas exotoxin containing immunotoxins. European Journal of Immunology, 1997, 27, 1459-1468.	1.6	31
215	GDEP, a new gene differentially expressed in normal prostate and prostate cancer. Prostate, 2001, 48, 231-241.	1.2	31
216	Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38. Molecular Cancer Therapeutics, 2010, 9, 1039-1046.	1.9	31

#	Article	IF	Citations
217	Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding. Cancer Research, 2011, 71, 5915-5922.	0.4	31
218	Phase 1 study of the immunotoxin LMBâ€100 in patients with mesothelioma and other solid tumors expressing mesothelin. Cancer, 2020, 126, 4936-4947.	2.0	31
219	Characterization of the 3,3â€²,5-Triiodo-L-Thyronine Binding Site on Plasma Membranes from Human Placenta. Endocrinology, 1985, 116, 2621-2630.	1.4	30
220	Reduced mRNA levels for the multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines. Journal of Cellular Physiology, 1992, 152, 87-94.	2.0	30
221	A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. Protein Engineering, Design and Selection, 2012, 25, 1-6.	1.0	30
222	Multidrug resistant transgenic mice as a novel pharmacologic tool. BioEssays, 1991, 13, 381-387.	1.2	29
223	Identification of Residues That Stabilize the Single-chain Fv of Monoclonal Antibodies B3. Journal of Biological Chemistry, 1995, 270, 23373-23380.	1.6	29
224	Antisense Inhibition of CAS, the Human Homologue of the Yeast Chromosome Segregation Gene CSE1, Interferes with Mitosis in HeLa Cells. Biochemistry, 1997, 36, 9493-9500.	1.2	29
225	Convection Enhanced Delivery of Macromolecules for Brain Tumors. Current Drug Discovery Technologies, 2012, 9, 305-310.	0.6	29
226	ANKRD26 and Its Interacting Partners TRIO, GPS2, HMMR and DIPA Regulate Adipogenesis in 3T3-L1 Cells. PLoS ONE, 2012, 7, e38130.	1.1	28
227	A Modified Form of Diphthamide Causes Immunotoxin Resistance in a Lymphoma Cell Line with a Deletion of the WDR85 Gene. Journal of Biological Chemistry, 2013, 288, 12305-12312.	1.6	28
228	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and antiâ€“PD-1 antibody in patients with mesothelioma and mouse tumor models. Science Translational Medicine, 2020, 12, .	5.8	28
229	Translocation chromosome 7 of A431 cells contains amplification and rearrangement of EGF receptor gene responsible for production of variant mRNA. Somatic Cell and Molecular Genetics, 1985, 11, 477-484.	0.7	27
230	Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques. Journal of Leukocyte Biology, 2006, 80, 1175-1182.	1.5	27
231	Detection of Multidrug Resistance (MDR1) Gene RNA Expression in Human Tumors by a Sensitive Ribonuclease Protection Assay. Japanese Journal of Cancer Research, 1989, 80, 1127-1132.	1.7	26
232	Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1: Conformational influence of an engineered disulfide bond. Proteins: Structure, Function and Bioinformatics, 1998, 31, 128-138.	1.5	26
233	Diminished content of plasma membrane-associated myosin in transformed fibroblasts. Nature, 1976, 261, 414-415.	13.7	25
234	A calcium requirement for movement of cultured cells. Journal of Cellular Physiology, 1979, 101, 101-108.	2.0	25

#	Article	IF	Citations
235	Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in anin vivo tumor model. International Journal of Cancer, 1994, 57, 856-864.	2.3	25
236	Isolation of anti-mesothelin antibodies from a phage display library. Molecular Immunology, 1997, 34, 9-20.	1.0	25
237	The T Cell Receptor Î³ Chain Alternate Reading Frame Protein (TARP), a Prostate-specific Protein Localized in Mitochondria. Journal of Biological Chemistry, 2004, 279, 24561-24568.	1.6	25
238	Designing the Furin-Cleavable Linker in Recombinant Immunotoxins Based on Pseudomonas Exotoxin A. Bioconjugate Chemistry, 2015, 26, 1120-1128.	1.8	25
239	Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay. Journal of Immunological Methods, 2004, 292, 141-155.	0.6	24
240	Toxin-Based Targeted Therapy for Malignant Brain Tumors. Clinical and Developmental Immunology, 2012, 2012, 1-15.	3.3	24
241	Immunoconjugates in the management of hairy cell leukemia. Best Practice and Research in Clinical Haematology, 2015, 28, 236-245.	0.7	24
242	Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A. Toxins, 2016, 8, 217.	1.5	24
243	TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. OncoImmunology, 2016, 5, e1197459.	2.1	24
244	Podocyte Injury Augments Intrarenal Angiotensin II Generation and Sodium Retention in a Megalin-Dependent Manner. Hypertension, 2019, 74, 509-517.	1.3	24
245	Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bclâ€2 expression. British Journal of Haematology, 2010, 148, 99-109.	1.2	23
246	Affinityâ€matured antiâ€glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. International Journal of Cancer, 2011, 129, 111-121.	2.3	23
247	Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leukemia and Lymphoma, 2011, 52, 82-86.	0.6	23
248	Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A. Journal of Immunological Methods, 2015, 425, 10-20.	0.6	23
249	Anti-TGF-Î² Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria. PLoS ONE, 2016, 11, e0155534.	1.1	23
250	SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors. Toxins, 2018, 10, 470.	1.5	23
251	Studies on the Activity of Barnase Toxinsin Vitroandin Vivoâ€. Bioconjugate Chemistry, 1996, 7, 23-29.	1.8	22
252	Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncatedpseudomonas exotoxin. International Journal of Cancer, 2001, 92, 861-870.	2.3	22

#	Article	IF	Citations
253	Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8. Leukemia Research, 2013, 37, 1551-1556.	0.4	22
254	Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results. Scientific Reports, 2015, 5, 10832.	1.6	22
255	Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1135-42.	3.3	22
256	Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer, 2015, 15, 376.	1.1	22
257	Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins. Molecular Cancer Therapeutics, 2016, 15, 1648-1655.	1.9	22
258	Regulation of Lac Transcription in Escherichia coli by Cyclic Adenosine 3',5'-Monophosphate. Journal of Biological Chemistry, 1970, 245, 6366-6372.	1.6	22
259	Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice. , 1996, 67, 113-123.		21
260	Attenuating the growth of tumors by intratumoral administration of DNA encoding Pseudomonas exotoxin via cationic liposomes. Cancer Gene Therapy, 2000, 7, 91-96.	2.2	21
261	Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody. Clinical Cancer Research, 2011, 17, 5926-5934.	3.2	21
262	Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38. Cellular Immunology, 2017, 313, 59-66.	1.4	21
263	Possible role of complement factor H in podocytes in clearing glomerular subendothelial immune complex deposits. Scientific Reports, 2019, 9, 7857.	1.6	21
264	Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer. Oncology Letters, 2020, 19, 1741-1750.	0.8	21
265	Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimericPseudomonas exotoxin. International Journal of Cancer, 1994, 58, 744-748.	2.3	20
266	Immunotoxins in the Treatment of Refractory Hairy Cell Leukemia. Hematology/Oncology Clinics of North America, 2006, 20, 1137-1151.	0.9	20
267	Immunotoxins with decreased immunogenicity and improved activity. Leukemia and Lymphoma, 2011, 52, 87-90.	0.6	20
268	Imaging of Convection Enhanced Delivery of Toxins in Humans. Toxins, 2011, 3, 201-206.	1.5	20
269	Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy. Biomolecules, 2020, 10, 979.	1.8	20
270	CYCLIC AMPâ€TREATED SARCOMA CELLS ACQUIRE SEVERAL MORPHOLOGICAL CHARACTERISTICS OF NORMAL FIBROBLASTS. Annals of the New York Academy of Sciences, 1971, 185, 413-416.	1.8	19

#	Article	IF	Citations
271	Chemical Modification to Reduce Renal Uptake of Disulfide-Bonded Variable Region Fragment of Anti-Tac Monoclonal Antibody Labeled with99mTc. Bioconjugate Chemistry, 1999, 10, 447-453.	1.8	19
272	Selective POTE Paralogs on Chromosome 2 are Expressed in Human Embryonic Stem Cells. Stem Cells and Development, 2008, 17, 325-332.	1.1	19
273	Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy. Clinical Cancer Research, 2012, 18, 152-160.	3.2	19
274	Combining the Antimesothelin Immunotoxin SS1P With the BH3-mimetic ABT-737 Induces Cell Death in SS1P-resistant Pancreatic Cancer Cells. Journal of Immunotherapy, 2014, 37, 8-15.	1.2	19
275	Effect of epidermal growth factor on prostaglandin E1 -stimulated accumulation of cyclic AMP in fibroblastic cells. FEBS Letters, 1979, 102, 329-332.	1.3	18
276	Inhibition by bacitracin of high affinity binding of 125 I-Î±2 M to plasma membranes. FEBS Letters, 1981, 126, 265-268.	1.3	18
277	EGF induces receptor down-regulation with no receptor recycling in KB cells. Journal of Cellular Physiology, 1985, 122, 166-170.	2.0	18
278	Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. Journal of Cellular Physiology, 1993, 155, 414-425.	2.0	18
279	Recombinant immunotoxins. Breast Cancer Research and Treatment, 1996, 38, 3-9.	1.1	18
280	Twisted Gastrulation, a BMP Antagonist, Exacerbates Podocyte Injury. PLoS ONE, 2014, 9, e89135.	1.1	18
281	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. Lung Cancer, 2016, 101, 104-110.	0.9	18
282	Development of Recombinant Immunotoxins for Hairy Cell Leukemia. Biomolecules, 2020, 10, 1140.	1.8	18
283	Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Research, 2012, 32, 5151-8.	0.5	18
284	Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. Molecular Cancer Therapeutics, 2022, 21, 1195-1206.	1.9	18
285	Comparison of Recombinant Immunotoxins against LeYAntigen Expressing Tumor Cells:Â Influence of Affinity, Size, and Stability. Bioconjugate Chemistry, 1998, 9, 736-743.	1.8	17
286	The Insulin Receptor Negatively Regulates the Action of Pseudomonas Toxin-Based Immunotoxins and Native Pseudomonas Toxin. Cancer Research, 2013, 73, 2281-2288.	0.4	17
287	Diphthamide affects selenoprotein expression: Diphthamide deficiency reduces selenocysteine incorporation, decreases selenite sensitivity and pre-disposes to oxidative stress. Redox Biology, 2019, 20, 146-156.	3.9	17
288	Multiple proteases are involved in mesothelin shedding by cancer cells. Communications Biology, 2020, 3, 728.	2.0	17

#	Article	IF	Citations
289	CD21^{â^'/low} Marginal Zone B Cells Highly Express Fc Receptorâ€"like 5 Protein and Are Killed by Antiâ€"Fc Receptorâ€"like 5 Immunotoxins in Hepatitis C Virusâ€"Associated Mixed Cryoglobulinemia Vasculitis. Arthritis and Rheumatology, 2014, 66, 433-443.	2.9	16
290	Global polysome analysis of normal and injured podocytes. American Journal of Physiology - Renal Physiology, 2019, 316, F241-F252.	1.3	16
291	Results from an international phase 2 study of the antiâ€CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood Bâ€lineage acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28112.	0.8	16
292	Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leukemia and Lymphoma, 2011, 52, 79-81.	0.6	15
293	The improvement of an anti-CD22 immunotoxin. MAbs, 2011, 3, 479-486.	2.6	15
294	POTE protein, a cancer-testis antigen, is highly expressed in spermatids in human testis and is associated with apoptotic cells. Biochemical and Biophysical Research Communications, 2012, 417, 1271-1274.	1.0	15
295	Identification and Enhancement of HLA-A2.1-Restricted CTL Epitopes in a New Human Cancer Antigen-POTE. PLoS ONE, 2013, 8, e64365.	1.1	15
296	Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors. Molecular Cancer Therapeutics, 2014, 13, 82-89.	1.9	15
297	Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1. Cancer Research, 2016, 76, 1560-1568.	0.4	15
298	Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia. Oncologist, 2020, 25, e170-e177.	1.9	15
299	Purification and Partial Characterization of an Interleukin 2-Pseudomonas Exotoxin Fusion Protein. Nature Biotechnology, 1988, 6, 1326-1329.	9.4	14
300	Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. , 1997, 71, 638-644.		14
301	Expression of POTE protein in human testis detected by novel monoclonal antibodies. Biochemical and Biophysical Research Communications, 2008, 365, 603-608.	1.0	14
302	Approach to the patient after relapse of hairy cell leukemia. Leukemia and Lymphoma, 2009, 50, 32-37.	0.6	14
303	Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering. Molecular Cancer Therapeutics, 2018, 17, 1486-1493.	1.9	14
304	Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4592-4598.	3.3	14
305	Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity. Molecular Cancer Therapeutics, 2020, 19, 812-821.	1.9	14
306	Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway. Oncotarget, 2017, 8, 87307-87316.	0.8	14

#	Article	IF	Citations
307	Effect of Antigen Shedding on Targeted Delivery of Immunotoxins in Solid Tumors from a Mathematical Model. PLoS ONE, 2014, 9, e110716.	1.1	13
308	Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome. British Journal of Haematology, 2014, 166, 729-738.	1.2	13
309	Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6086-6091.	3.3	13
310	Stabilization of hypoxia-inducible factor ameliorates glomerular injury sensitization after tubulointerstitial injury. Kidney International, 2021, 99, 620-631.	2.6	13
311	Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P. PLoS ONE, 2013, 8, e75576.	1.1	13
312	Modulating Mesothelin Shedding to Improve Therapy. Oncotarget, 2012, 3, 114-115.	0.8	13
313	Fluorescent rhodamine-labeled thyroid hormone derivatives. FEBS Letters, 1979, 100, 113-116.	1.3	12
314	An epidermal growth factor-ricin a chain (EGF-RTA)-resistant mutant and an epidermal growth factor-Pseudomonas endotoxin (EGF-PE)-resistant mutant have distinct phenotypes. Journal of Cellular Physiology, 1989, 139, 51-57.	2.0	12
315	Autonomic neuropathy in transgenic mice caused by immunotoxin targeting of the peripheral nervous system. , 1998, 51, 162-173.		12
316	5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1867-E1875.	3.3	12
317	Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary. PLoS ONE, 2012, 7, e47320.	1.1	12
318	Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line. PLoS ONE, 2015, 10, e0122462.	1.1	12
319	Immunotoxins in cancer therapy. Current Opinion in Investigational Drugs, 2002, 3, 1089-91.	2.3	12
320	In situLocalization of the Human Multidrug-resistance Gene mRNA Using Thymine-Thymine Dimerized Single-stranded cDNA. Japanese Journal of Cancer Research, 1990, 81, 949-955.	1.7	11
321	Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma. , 1998, 36, 162-167.		11
322	Tumor and organ uptake of 64Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies. Nuclear Medicine and Biology, 2015, 42, 880-886.	0.3	11
323	Bortezomib Reduces Pre-Existing Antibodies to Recombinant Immunotoxins in Mice. Journal of Immunology, 2015, 194, 1695-1701.	0.4	11
324	Immunotherapy-based targeting of MSLN ⁺ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	11

#	Article	IF	Citations
325	EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery. Receptors & Clinical Investigation, 2016, 3, .	0.9	11
326	Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies. Oncotarget, 2017, 8, 30644-30655.	0.8	11
327	Rous sarcoma virus transformed cells are resistant to cyclic AMP. Journal of Cellular Physiology, 1982, 111, 42-48.	2.0	10
328	Mutant KB cells with decreased EGF receptor expression: Biochemical characterization. Journal of Cellular Physiology, 1987, 133, 127-134.	2.0	10
329	Genetic characterization of human KB cell lines resistant to epidermal growth factor:Pseudomonas exotoxin conjugates. Journal of Cellular Physiology, 1988, 135, 527-532.	2.0	10
330	Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1. Cellular Immunology, 2018, 334, 38-41.	1.4	10
331	Reduction of EGF receptor synthesis by antisense RNA vectors. FEBS Letters, 1986, 206, 319-322.	1.3	9
332	Anti-prostate immunotoxins: Cytotoxicity of E4 antibodyâ€“pseudomonas exotoxin constructs. , 1998, 77, 123-127.		9
333	Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin Aâ€“Based Immunotoxins. Molecular Cancer Therapeutics, 2016, 15, 1053-1062.	1.9	9
334	Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin. Journal of Immunology, 2018, 200, 2038-2045.	0.4	9
335	Lipoprotein modulation of proteinuric renal injury. Laboratory Investigation, 2019, 99, 1107-1116.	1.7	9
336	Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia. British Journal of Clinical Pharmacology, 2020, 86, 1367-1376.	1.1	9
337	Indirect podocyte injury manifested in a partial podocytectomy mouse model. American Journal of Physiology - Renal Physiology, 2021, 320, F922-F933.	1.3	9
338	Phosphorylation of the solubilized insulin receptor by the gene product of the Rous sarcoma virus, pp60src. Journal of Cellular Biochemistry, 1984, 26, 169-179.	1.2	8
339	Epidermal growth factor-dependent growth of human KB cells in a defined medium and altered growth factor requirements of KB mutants resistant to EGF-Pseudomonas exotoxin conjugates. Journal of Cellular Physiology, 1988, 135, 502-508.	2.0	8
340	Efficient ablation by immunotoxin-mediated cell targeting of the cell types that express human interleukin-2 receptor depending on the internal ribosome entry site. Journal of Gene Medicine, 2001, 3, 505-510.	1.4	8
341	Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009. Acta Crystallographica Section F: Structural Biology Communications, 2012, 68, 950-953.	0.7	8
342	Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design. Clinical Cancer Research, 2016, 22, 4913-4922.	3.2	8

#	Article	IF	Citations
343	Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia. Toxins, 2018, 10, 210.	1.5	8
344	Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia. Leukemia and Lymphoma, 2021, 62, 2812-2814.	0.6	8
345	Recombinant Immunotoxins for Treating Cancer. , 2010, , 127-146.		8
346	Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial. Blood, 2019, 134, 2808-2808.	0.6	8
347	Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice. PLoS ONE, 2014, 9, e104388.	1.1	8
348	Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins. PLoS ONE, 2016, 11, e0161415.	1.1	8
349	Advances in the Development of Anti-CD22 Immunotoxins Containing Pseudomonas Exotoxin for Treatment of Hematologic Malignancies. Journal of Cancer Science & Therapy, 2011, 03, .	1.7	8
350	Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2202439119.	3.3	8
351	Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancerâ€”a preclinical study. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	8
352	Putative â€œMDR enhancerâ€•is located on human chromosome 20 and not linked to theMDRI gene on chromosome 7. Genes Chromosomes and Cancer, 1994, 10, 267-274.	1.5	7
353	Palmitoylation of POTE family proteins for plasma membrane targeting. Biochemical and Biophysical Research Communications, 2007, 363, 751-756.	1.0	7
354	Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma. Antibody Therapeutics, 2018, 1, 19-25.	1.2	7
355	Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer. Clinical Colorectal Cancer, 2019, 18, 192-199.e1.	1.0	7
356	Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 839-839.	0.6	7
357	Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.. Blood, 2009, 114, 888-888.	0.6	7
358	Effect of cell density on energy-dependent calcium uptake by Balb/c 3T3 membranes is independent of protein synthesis and attachment to substratum. Journal of Cellular Physiology, 1979, 101, 109-116.	2.0	6
359	Pseudomonas exotoxin: recombinant conjugates as therapeutic agents. Biochemical Society Transactions, 1992, 20, 731-734.	1.6	6
360	Cytotoxic effect of a fusion protein from transforming growth factora andPseudomonas exotoxin on rat and human bladder carcinoma cells in vitro. Journal of Cancer Research and Clinical Oncology, 1994, 120, 507-512.	1.2	6

#	Article	IF	Citations
361	Sensitivity of human acute myeloid leukaemia to diphtheria toxin-GM-CSF fusion protein. British Journal of Haematology, 1997, 98, 952-959.	1.2	6
362	Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. Clinical Chemistry and Laboratory Medicine, 2006, 44, 594-602.	1.4	6
363	Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. journal of applied laboratory medicine, The, 2018, 3, 166-177.	0.6	6
364	The Cellular Entry of EGF and Transferrin: A Problem in Intracellular Sorting. Current Topics in Cellular Regulation, 1985, 26, 17-25.	9.6	6
365	Immunotoxins: From Design to Clinical Application. Biomolecules, 2021, 11, 1696.	1.8	6
366	TGFÎ±-PE38 enhances cytotoxic T-lymphocyte killing of breast cancer cells. Oncology Letters, 2014, 7, 2113-2117.	0.8	5
367	Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy. Frontiers in Oncology, 2018, 8, 553.	1.3	5
368	Pre-Clinical Evaluation of the Anti-CD22 Immunotoxin CAT-8015 in Combination with Chemotherapy Agents for Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL).. Blood, 2007, 110, 865-865.	0.6	5
369	Adenylate cyclase in a fibroblast mutant defective in glycolipid and glycoprotein synthesis. Nature, 1978, 275, 223-224.	13.7	4
370	Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccines. The Histochemical Journal, 1999, 31, 729-737.	0.6	4
371	Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens. Journal of Biomolecular Screening, 2016, 21, 942-955.	2.6	4
372	Role of HLA-DP in the Presentation of Epitopes from the Truncated Bacterial PE38 Immunotoxin. AAPS Journal, 2017, 19, 117-129.	2.2	4
373	Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy. Journal of Immunotherapy, 2019, 42, 119-125.	1.2	4
374	Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox. Blood, 2013, 122, 2871-2871.	0.6	4
375	GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling. Molecular Cancer Therapeutics, 2022, 21, 960-973.	1.9	4
376	Interplay between reversible phosphorylation and irreversible ADP-ribosylation of eukaryotic translation elongation factor 2. Biological Chemistry, 2019, 400, 501-512.	1.2	3
377	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors.. Journal of Clinical Oncology, 2021, 39, TPS452-TPS452.	0.8	3
378	Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer.. Journal of Clinical Oncology, 2021, 39, 3051-3051.	0.8	3

#	Article	IF	Citations
379	Abstract 4510: RG7787 - a novel de-immunized PE based fusion protein for therapy of mesothelin-positive solid tumors. Cancer Research, 2014, 74, 4510-4510.	0.4	3
380	Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox. Blood, 2010, 116, 3246-3246.	0.6	3
381	Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy. Blood, 2011, 118, 2575-2575.	0.6	3
382	High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome. Blood, 2015, 126, 4161-4161.	0.6	3
383	A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 307-307.	0.8	3
384	Unilateral ureteral obstruction attenuates intrarenal angiotensin II generation induced by podocyte injury. American Journal of Physiology - Renal Physiology, 2015, 308, F932-F937.	1.3	2
385	Decreased accumulation of [14c]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. , 2000, 183, 108.		2
386	Mesothelin expression in patients as a novel target in gastric cancer.. Journal of Clinical Oncology, 2014, 32, 61-61.	0.8	2
387	Epitope Blocking: Positive and Negative Effects on the Biodistribution of125I-Labeled Anti-Tac Disulfide-stabilized Fv Fragment of Two Antibodies against Different Epitopes of the Circulating Antigen. Japanese Journal of Cancer Research, 1998, 89, 436-444.	1.7	1
388	An NIH Career: from Bedside to Basic Research and Back. Journal of Biological Chemistry, 2005, 280, 18553-18557.	1.6	1
389	Exploiting bias in a non-immune human antibody library to predict antigenicity. Protein Engineering, Design and Selection, 2011, 24, 845-853.	1.0	1
390	Factors that Determine Sensitivity and Resistances of Tumor Cells Towards Antibody-Targeted Protein Toxins. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 57-73.	0.1	1
391	BL22, a Recombinant Anti-CD22 Immunotoxin, Induces Cell Cycle Arrest and Apoptosis in B-Cell Lymphoma.. Blood, 2004, 104, 4613-4613.	0.6	1
392	Targeting CD22 in Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL): Pre-Clinical Studies and Phase I Trial of the Anti-CD22 Immunotoxin CAT-3888 (BL22).. Blood, 2007, 110, 855-855.	0.6	1
393	Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.. Blood, 2009, 114, 3442-3442.	0.6	1
394	Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.. Blood, 2012, 120, 2896-2896.	0.6	1
395	Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia.. Journal of Clinical Oncology, 2015, 33, 7079-7079.	0.8	1
396	A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors.. Journal of Clinical Oncology, 2017, 35, 102-102.	0.8	1

#	Article	IF	Citations
397	Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.. Journal of Clinical Oncology, 2021, 39, 7036-7036.	0.8	0
398	Clinical Applications of Gene Therapy in Cancer: Modification of Sensitivity to Therapeutic Agents. , 0, , 429-453.		0
399	ILâ€2 nonâ€responsive subset of human natural regulatory T cells expresses Fc receptorâ€like 3 protein. FASEB Journal, 2008, 22, 381-381.	0.2	0
400	Durability of complete remission by moxetumomab pasudotox (HA22 or CAT-8015) assessed by clone-specific real-time quantitative PCR (RQ-PCR).. Journal of Clinical Oncology, 2012, 30, 2503-2503.	0.8	0
401	Decreased Expression of Diphthamide Genes Is Responsible for the Resistance to the Anti-CD22 Immunotoxin Moxetumomab Pasudotox (m. pasudotox) in Acute Lymphoblastic Leukemia (ALL)/Non-Hodgkin Lymphoma (NHL) Cell Lines.. Blood, 2012, 120, 2443-2443.	0.6	0
402	The HLA-DRB1*11 Antigen Is Preferentially Expressed in Hairy Cell Leukemia, Particularly in Patients Who Had Hemolytic Uremic Syndrome with Recombinant Immunotoxin BL22.. Blood, 2012, 120, 2488-2488.	0.6	0
403	A New High Activity Anti-CD22 Chimeric Antigen Receptor (CAR) Targeting B Cell Leukemia.. Blood, 2012, 120, 2611-2611.	0.6	0
404	Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4.. Journal of Clinical Oncology, 2017, 35, 74-74.	0.8	0
405	Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.. Journal of Clinical Oncology, 2019, 37, 7014-7014.	0.8	0